52 Week Range
- Open Price
- Previous Close
Start SIP inStart SIP
Jfl Life Sciences has an operating revenue of Rs. 94.72 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 2% needs improvement, ROE of 7% is fair but needs improvement. The company has a high debt to equity of 119%, which can be a reason to worry. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 1 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 171 indicates it belongs to a poor industry group of Medical-Whlsle Drg/Suppl and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.
NSE-Medical-Whlsle Drg/SupplJfl Life Sciences belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 32.77 Cr. and Equity Capital is Rs. 0.50 Cr. for the Year ended 31/03/2021. JFL Life Sciences Ltd. is a Public Limited Listed company incorporated on 25/04/2010 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is U24230GJ2010PLC060417 and registration number is 060417.
|Shares in Float||0.36|
|No of funds|
|U/D Vol ratio||0.4|
|LTDebt / Equity||119|
|Mr. Smiral Ashwinkumar Patel||Chairman & Managing Director|
|Mr. Manishkumar Jasvantlal Patel||Non Executive Director|
|Mrs. Tejal Smiral Patel||Whole Time Director|
|Ms. Sonu Lalitkumar Jain||Independent Director|
|Ms. Bhavna Shah||Independent Director|
What is Share Price of ?
share price is ₹ As on 02 December, 2022 | 17:21